Table 4 Comparison of clinical parameters of patients treated with MP who improved and progressed
| Â | Â | improvement | progression | P value |
|---|---|---|---|---|
|  |  | (n = 49) | (n = 8) | |
Age, years, median (range) |  | 53 (19–74) | 65.5 (47–74) | 0.0118 |
Gender, n (%) | Male | 31 (63) | 5 (63) | > 0.9999 |
| Â | Female | 18 (37) | 3 (38) | |
DM, n (%) | Â | 10 (20) | 3 (38) | 0.3653 |
BMI, kg/m2, median (range) |  | 22 (17.0–29.6) | 22.8 (18.8–28.8) | 0.2104 |
|  | > 25, n (%) | 5 (10) | 3 (38) | 0.0742 |
Use of MMF as maintenance immunosuppression, n (%) |  | 30 (61) | 5 (63) | > 0.9999 |
Time from symptom onset to MP treatment, days, median (range) |  | 1 (0–5) | 2.5 (1–10) | 0.0430 |
Baseline eGFR, ml/min/1.73m2, median (range) |  | 46 (19.2–99.5) | 44.45 (18.3–73.5) | 0.9451 |
|  | < 30, n (%) | 4 (8) | 2 (25) | 0.1943 |
Previous SARS-CoV-2 vaccine, doses, median (range) |  | 4 (2–6) | 4 (0–5) | 0.8933 |